# Aminopterin/methotrexate embryofetopathy

INSERM

## Source

INSERM. (1999). *Orphanet: an online rare disease and orphan drug data base.*

*Aminopterin/methotrexate embryofetopathy*. ORPHA:1908

Aminopterin/Methotrexate embryofetopathy is a syndrome of developmental anomalies characterized by growth deficiency, facial dysmorphism and skull, limb and neural defects secondary to maternal exposure to aminopterin or methotrexate (MTX) during pregnancy.